7 completed, 4 recruiting, 2 terminated. 7 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Ocular Hypertension (OHT): new trials by email Literature Review of Ocular Hypertension (OHT) trials Research Report on Ocular Hypertension (OHT)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| iDose TR Administration in an Office-Based Surgery Setting iDose TR (travoprost intracameral implant) 75 µg - Open Angle Glaucoma (OAG), Ocular Hypertension (OHT) | Recruiting | Glaukos Corporation | 30 | 2026-05-13 | 2026-09-30 | |
| Direct vs Standard SLT for Glaucoma: A Noninferiority Trial Direct Selective laser Trabeculoplasty - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Not applicable | Recruiting | Medical University of South Carolina | 172 | 2026-04-27 | 2026-05-06 |
| Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery - Glaucoma, Open-angle, Ocular Hypertension (OHT) | Phase 4 | Recruiting | Glaukos Corporation | 132 | 2025-01-13 | 2026-01-21 |
| Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075% - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Qlaris Bio, Inc. | 36 | 2024-04-21 | 2025-01-20 |
| Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%) - Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes | Phase 2 | Completed | Qlaris Bio, Inc. | 63 | 2024-03-05 | 2025-01-20 |
| Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 201 | 2016-08-19 | 2018-02-15 |
| Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 3 | Completed | Inotek Pharmaceuticals Corporation | 303 | 2015-09-01 | 2016-12-06 |
| Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension DWT device dose A, Ellex Tango SLT machine, DWT device dose B - Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Terminated | OcuTherix, Inc. | 35 | 2013-11-01 | 2017-04-04 |
| A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 101 | 2013-08-01 | 2017-12-02 |
| Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma ONO-9054, Placebo - Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG) | Phase 1 | Completed | Ono Pharma USA Inc | 60 | 2012-08-01 | 2013-06-03 |
| AL-54478 Proof of Concept Study AL-54478 0.005%, Latanoprost 0.005%, AL-54478 Vehicle - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Alcon Research | 64 | 2011-06-01 | 2014-07-31 |
| Safety Study of Latanoprost Slow Release Insert Latanoprost, Arm 2, Latanoprost SR insert - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 | Terminated | Daniel Moore | 12 | 2011-01-01 | 2014-12-08 |
Glaucoma, Open-Angle (13) · Ocular Hypertension (13) · Glaucoma (9) · Eye Diseases (1)
Eye Diseases (12) · Glaucoma (4)
Latanoprost (3) · trabodenoson (3) · INO-8875 (2) · Timolol (2) · BID protein, human (1) · Cataract Extraction (1) · DMAC2L protein, human (1) · propan-2-yl 4-(6-(4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-hydroxyoctahydro-2H-cyclopenta(b)oxepin-3-yl)butanoate (1)
Inotek Pharmaceuticals Corporation (3) · Glaukos Corporation (2) · Qlaris Bio, Inc. (2) · Alcon Research (1) · Daniel Moore (1) · Medical University of South Carolina (1) · OcuTherix, Inc. (1) · Ono Pharma USA Inc (1) · Regeneron Pharmaceuticals (1)
United States (11) · Philippines (1)
Cadmus C Rich, MD,MBA,CPE (2) · Lisa Brandano (2) · Daniel B. Moore, M.D. (1) · Edgar U. Leuenberger, MD (1) · Harvey Siy Uy, MD (1) · Jella An, MD (1) · Maria I Yap-Veloso, MD (1) · Ravaughn Williams (1)